First Copy of J&J’s $6 Billion Remicade Wins EMA Backing
This article is for subscribers only.
Celltrion Inc. and Hospira Inc. won European backing to sell the first copies of Johnson & Johnson’s Remicade, a $6 billion arthritis therapy, as regulators open the door to cheaper versions of the world’s best-selling medicines.
The European Commission should give the two companies approval to market their versions, called Remsima and Inflectra, for the same medical conditions for which Remicade is marketed, the European Medicines Agency said in a statement today.